Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5

VIENNA, Austria–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from two studies evaluating the safety and efficacy of investigational uses of sofosbuvir-based regimens in chronic hepatitis C virus (HCV)-infected patients with genotypes 2, 3, 4 and 5. Results from the BOSON study of Sovaldi® (sofosbuvir 400 mg) in combination with ribavirin (RBV) or with […]

Read More »

New Data Shows Greater In Vitro Potency for VIBATIV(R) (Telavancin) Against Multidrug-Resistant Gram-Positive Bacteria, Including MRSA, Compared to Alternative Antibiotic Treatments

Data Presentations at 2015 ECCMID Conference Highlight Key Findings in Light of the Growing Global Threat of Antibiotic Resistance GEORGE TOWN, GRAND CAYMAN–(Marketwired – Apr 24, 2015) – Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma” or the “Company”) today announced new positive data from studies of VIBATIV® (telavancin), the Company’s FDA-approved antibiotic. These studies’ results will […]

Read More »

Exercise Can't Save Us: Our Sugar Intake Is The Real Culprit, Say Experts

In a fascinating and scorching editorial in the British Journal of Sports Medicine, three authors argue that the myth that exercise is the key to weight loss – and to health – is erroneous and pervasive, and that it must end. The evidence that diet matters more than exercise is now overwhelming, they write, and […]

Read More »

Tolero Pharmaceuticals Presents Data Demonstrating Profound Synergy of Alvocidib and Bromodomain Protein Inhibitors in Nonclinical Models of Acute Myeloid Leukemia

SALT LAKE CITY–(BUSINESS WIRE)–Tolero Pharmaceuticals, Inc, today announced that it presented nonclinical study results demonstrating profound synergy of lead candidate, alvocidib, and bromo and extra terminal (BET) protein inhibitors in acute myeloid leukemia (AML) models at the 2015 American Association for Cancer Research Annual Meeting in Philadelphia, PA. Alvocidib is a CDK9 inhibitor in clinical development for […]

Read More »

Feeling grateful may improve health for heart failure patients

<span class="articleLocation”>(Reuters Health) – Feeling grateful may help heart failure patients heal both physically and emotionally, say U.S. researchers. Gratitude was linked to better sleep and mood, as well as lower levels of inflammation in people coping with heart failure in a California study. Lead author Paul Mills said in an email that previous studies […]

Read More »

Chinese Scientists Try To Alter Genomes In Human Embryos

Bet you did not know that today is National DNA Day. It is. But before we all begin to party over our biological programming, remember this is also the day when the world is trying to figure out how to respond to a paper from a team of scientists in China stating that they tried […]

Read More »

Mayo Clinic Researchers Identify Methylated DNA Markers That May One Day Lead To Noninvasive Whole Body Cancer Screening

Philadelphia – WEBWIRE – Friday, April 24, 2015 A team of Mayo Clinic researchers has succeeded in identifying the source of cancer in patients’ gastrointestinal tracts by analyzing DNA markers from tumors. The results open the possibility that doctors could one day be able to screen for cancer anywhere in the body with a noninvasive […]

Read More »

World’s first malaria vaccine moves closer to use in Africa

(Reuters) – The world’s first malaria vaccine, made by GlaxoSmithKline, could be approved by international regulators for use in Africa from October after final trial data showed it offered partial protection for up to four years. The shot, called RTS,S and designed for children in Africa, would be the first licensed human vaccine against a […]

Read More »

AstraZeneca insists Celgene deal about strategy, not cash

(Reuters) – AstraZeneca (AZN.L) is getting a $450 million windfall by letting Celgene (CELG.O) develop a prized immunotherapy drug for blood cancers but its chief executive insists the deal is about strategy, not cash. Some investors are worried about the drugmaker’s reliance on such “externalization” deals to fill a short-term revenue gap. Deutsche Bank analyst […]

Read More »

Mylan To Commence Formal Offer To Acquire Perrigo For US$60 In Cash And 2.2 Mylan Shares Per Perrigo Share

POTTERS BAR, England, April 24, 2015 /PRNewswire/ — On 8 April 2015, Mylan N.V. (NASDAQ: MYL) issued a Rule 2.4 announcement under the Irish Takeover Rules stating that it had made a non-binding proposal to acquire Perrigo (NYSE: PRGO; TASE) for US$205 in a combination of cash and Mylan stock for each Perrigo share. The Rule 2.4 […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom